大和研究报告指，泰格医药(03347.HK) 发盈喜，预期2025年收入按年增长1%至16%，至66.6亿至76.8亿元人民币(下同)，在2024年跌11%后重拾增长。料净利润按年上升105%至204%，至8.3亿至12.3亿元；经常性净利润按年下跌43%至61%，至3.3亿至4.9亿元，主要由于订单取消、订单单价下降以及团队扩张相关营运成本增加。展望2026年，该行估计公司收入将按年增长16%...
Source Link大和研究报告指，泰格医药(03347.HK) 发盈喜，预期2025年收入按年增长1%至16%，至66.6亿至76.8亿元人民币(下同)，在2024年跌11%后重拾增长。料净利润按年上升105%至204%，至8.3亿至12.3亿元；经常性净利润按年下跌43%至61%，至3.3亿至4.9亿元，主要由于订单取消、订单单价下降以及团队扩张相关营运成本增加。展望2026年，该行估计公司收入将按年增长16%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.